Forty @entity1 , with mainly poor risk haematological @entity5 , were given the new regimen FLAG, comprising @entity3118 , @entity2592 and @entity1261 . Twenty four @entity1 had @entity3052 ( @entity3052 ), 8 @entity1 @entity2590 ( @entity2590 ) and a further 8 @entity1 had a variety of other haematological @entity5 . The response rates for 19 relapsed and 4 refractory @entity3052 @entity1 were 68% and 100% respectively and comparable to those attained using other regimens, although the numbers are small. Of 8 @entity1 with @entity2590 , 7 showed some response with 4 remaining in an improved disease status 5-12 months after FLAG. Follow-up has been too short thus far to provide any survival data in both @entity1 groups. In general, the other smaller group of 8 @entity1 (3 transformed @entity1860 ( @entity1860 ), 3 @entity981 ( @entity981 ), 2 @entity4585 ( @entity4585 ) did poorly with response shown in 1 only. The regimen was well tolerated with 4 procedure-related @entity1398 deaths. The @entity1398 and @entity882 periods are generally short when compared with those from current protocols. The overall modest @entity137 may encourage combination with other anti-leukaemic agents and be of particular use in the aged or heavily pre-treated @entity1 . Preliminary results may favour the setting up of controlled trials to properly evaluate the benefit of FLAG.

FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukaemia', 'ALL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenic'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity4585 :: ('MESH:D023981', 'Disease') :: ['granulocytic sarcoma', 'GS'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['arabinosyl cytosine'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukaemia', 'AML'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukaemia']
@entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndromes']
